<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00162604</url>
  </required_header>
  <id_info>
    <org_study_id>2602-415</org_study_id>
    <nct_id>NCT00162604</nct_id>
  </id_info>
  <brief_title>Prophylactic Antibiotic Treatment During Vaginal Repair</brief_title>
  <official_title>Antibiotikaprofylakse Ved Vaginalplastik</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <brief_summary>
    <textblock>
      Prolapse of the uterus, bladder and rectum is a common condition in multiparous and/or
      elderly women. The number of operations for vaginal repair is increasing in Denmark, but
      there is no consensus or evidence found about the efficiency of prophylactic antibiotics
      intraoperatively concerning postoperative infections.

      The objective of this randomized, controlled trial is to investigate the significance of
      prophylactic antibiotic treatment in vaginal repair operations.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2005</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>primary endpoint: no infections (urinary tract infections, pneumonia,wound infections, infected haematomas, etc.) within 30 days postoperatively</measure>
  </primary_outcome>
  <enrollment>200</enrollment>
  <condition>Uterine Prolapse</condition>
  <condition>Cystocele</condition>
  <condition>Rectocele</condition>
  <condition>Enterocele</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefuroxime</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women ages 18+ with uterine prolapse grade I - II and/or cystocele and/or rectocele
             and/or enterocele grade I - II and/or defects of the perineal body, in whom there is
             medical indication for vaginal repair, but no indication for vaginal hysterectomy or
             transvaginal suspension of the vaginal vault after prior hysterectomy.

        Exclusion Criteria:

          -  Patients allergic to cefuroxime.

          -  Patients in whom a vaginal hysterectomy or a transvaginal suspension of the vaginal
             vault or other major surgery is planned, where prophylactic antibiotic treatment is
             standard.

          -  Patients suffering from physical or mental disorders that will not allow them to give
             informed consent.

          -  Pregnant and nursing women.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne Ottesen, M.D, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marianne Ottesen, M.D</last_name>
    <phone>0045 36323632</phone>
    <phone_ext>3540</phone_ext>
    <email>marianne.8sen@dadlnet.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Ottesen, M.D</last_name>
      <phone>0045 36323632</phone>
      <phone_ext>3540</phone_ext>
      <email>marianne.8sen@dadlnet.dk</email>
    </contact>
    <investigator>
      <last_name>Tina Olsen, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abelone Elisabeth Sakse, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marianne Ottesen, M.D, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2005</study_first_posted>
  <last_update_submitted>September 8, 2006</last_update_submitted>
  <last_update_submitted_qc>September 8, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2006</last_update_posted>
  <keyword>Prophylactic antibiotic</keyword>
  <keyword>Postoperative infections</keyword>
  <keyword>Uterine prolapse grade I - II</keyword>
  <keyword>cystocele</keyword>
  <keyword>rectocele</keyword>
  <keyword>enterocele</keyword>
  <keyword>defects of the perineal body</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Cystocele</mesh_term>
    <mesh_term>Uterine Prolapse</mesh_term>
    <mesh_term>Rectocele</mesh_term>
    <mesh_term>Hernia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Cefuroxime</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

